PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS Real world ischaemic event reduction with PCSK9i mAbs Inclisiran role in plaque stabilisation Discontinuing PCSK9i leads to increased MACE V-MONO trial of inclisiran monotherapy meets primary endpoints

Meta-Analysis

New network meta-analysis of PCSK9 inhibitor efficacy

This analysis reaffirms the efficacy of PCSK9 monoclonal antibody therapy added to medium- to high-intensity statin therapy in lowering LDL cholesterol. The authors reviewed 69 trials of lipid-lowering therapies that enrolled patients requiring further LDL cholesterol reduction while on maximally tolerated medium- or high-intensity statin…

Posted on 18 October 2017 | Posted in News

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters